Home
Conditions
Neuroectodermal Tumors

Clinical trial condition

Neuroectodermal Tumors

Explore clinical trials studying Neuroectodermal Tumors. Study availability and eligibility vary by location and protocol.

5,995 public trials 1,209 recruiting studies

Refine in advanced search Browse all conditions

Neuroectodermal Tumors trial results

Recruiting

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

NCT06418204

Conditions: Breast Carcinoma, Breast Diseases, Breast Neoplasms, +39 more
Locations: Fairbanks Memorial Hospital Fairbanks, Alaska, United States

Kingman Regional Medical Center Kingman, Arizona, United States

Cancer Center at Saint Joseph's Phoenix, Arizona, United States

Mercy Hospital Fort Smith Fort Smith, Arkansas, United States

View all 467 locations

View Trial Details

Recruiting

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

NCT04943848

Conditions: Brain Diseases, Brain Neoplasms, Brain Stem Neoplasms, +16 more
Locations: Children's Health Orange County (CHOC) Orange, California, United States

Ann and Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States

Dana-Farber Boston Children's Cancer and Blood Disorders Center Boston, Massachusetts, United States

View Trial Details

Recruiting

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

NCT05746208

Conditions: High Grade Neuroendocrine Carcinoma, Any Site, Neoplasms, Neoplasms by Histologic Type, +5 more
Locations: University of California, San Francisco San Francisco, California, United States

View Trial Details

Recruiting

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

NCT06926075

Conditions: Adnexal Diseases, Astrocytoma, Breast Cancer, +47 more
Locations: St George Private Hospital Kogarah, New South Wales, Australia

South Western Sydney Local Health District Liverpool, New South Wales, Australia

Southside Cancer Centre Miranda, New South Wales, Australia

View Trial Details

Recruiting

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

NCT04119024

Conditions: Acral Melanoma, Adenocarcinoma, Adenocarcinoma of Lung, +59 more
Locations: City of Hope Duarte, California, United States

UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States

Stanford Cancer Institute Stanford, California, United States

View Trial Details

Recruiting

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401

Conditions: Astrocytoma, EGFR Gene Mutation, Glioblastoma, +10 more
Locations: University of California, San Francisco San Francisco, California, United States

View Trial Details

Recruiting

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

NCT07076550

Conditions: Eye Diseases, Eye Neoplasms, Melanoma, +21 more
Locations: Alfred Health Melbourne, Victoria, Australia

Austin Health Melbourne, Victoria, Australia

Fiona Stanley Hospital Murdoch, Western Australia, Australia

GenesisCare Murdoch Murdoch, Western Australia, Australia

View Trial Details

Recruiting

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

NCT01804634

Conditions: Hepatoblastoma, Myosarcoma, Neoplasms, +19 more
Locations: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States

Albert Einstein College of Medicine, Children's Hospital at Montefiore The Bronx, New York, United States

New York Medical Center/ Maria Fareri Children's Hospital Valhalla, New York, United States

View Trial Details

Recruiting

A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks

NCT07469709

Conditions: Adnexal Diseases, Breast Cancer, Breast Diseases, +46 more
Locations: Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo Candiolo, Turin, Italy

View Trial Details

Recruiting

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

NCT07364474

Conditions: Eye Diseases, Eye Neoplasms, Melanoma, +15 more
Locations: Massachusetts General Hospital Boston, Massachusetts, United States

View Trial Details

Neuroectodermal Tumors

Neuroectodermal Tumors trial results

Related conditions